Figures & data
Figure 1 Pathophysiology of CF lung disease and potential therapies targeting the basic defect or the symptoms.
Abbreviations: CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator; ENaC, epithelial sodium channel; mRNA, messenger RNA.
![Figure 1 Pathophysiology of CF lung disease and potential therapies targeting the basic defect or the symptoms.](/cms/asset/bff5b6ec-d0c2-4bce-affe-84a57ecb5799/dcpa_a_100759_f0001_c.jpg)
Figure 2 Predicted topology of CFTR protein.
Abbreviations: CFTR, cystic fibrosis transmembrane conductance regulator; MSD, membrane-spanning domain; NBD, nucleotide-binding domain; TMD: transmembrane domain; R, regulatory domain.
![Figure 2 Predicted topology of CFTR protein.](/cms/asset/45cfe2da-87c2-48dd-b95e-63c17c1448b9/dcpa_a_100759_f0002_c.jpg)
Table 1 Classes of CFTR mutations
Figure 3 Overview of the most advance CFTR modulators in preclinical and clinical studies, with regard to the class of CFTR mutations and the primary defect of the corresponding mutant protein.
![Figure 3 Overview of the most advance CFTR modulators in preclinical and clinical studies, with regard to the class of CFTR mutations and the primary defect of the corresponding mutant protein.](/cms/asset/0b93a99b-daa9-4e5a-adec-b548ca029c1b/dcpa_a_100759_f0003_c.jpg)
Table 2 Mechanisms of action of pharmacological modulators of CFTR available to CF patients or under preclinical development as mono- and/or combitherapies for CF